Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock Price
CRBPStock
$4.52−76.27%52W
Market Cap$87.42M
P/E—
PEG Ratio—
Div yield—
Beta2.77
CRBP Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-64.80%
Price vs S&P 500 (4W)-39.59%
VGM Score28.57
CRBP Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$1.24 | -$1.81 | -46.32%(-$0.57) | |
| Q1 2026 | -$1.22 | -$1.23 | -0.82%(-$0.01) | |
| Q4 2025 | -$1.58 | -$1.25 | +20.69%(+$0.33) | |
| Q3 2025 | -$1.71 | -$1.90 | -11.31%(-$0.19) | |
| Q2 2025 | -$1.33 | -$1.44 | -8.36%(-$0.11) |
CRBP Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.38
4.38
4.38
4.38
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
CRBPCorbus Pharmaceuticals Holdings, Inc. | D | — | F | 56.4x | — | — | — | $4.52 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals is a biopharmaceutical company developing precision therapeutics for oncology and metabolic disorders. Its pipeline includes CRB-701, an antibody-drug conjugate targeting Nectin-4 in cancer; CRB-601, an anti-integrin antibody designed to block TGF activation; and CRB-913, a CB1 receptor inverse agonist for obesity. These programs target validated biological pathways to address serious diseases.